The Journal of Allergy and Clinical Immunology
Volume 118, Issue 1 , Pages 257-268 , July 2006

Resistin-like molecule β regulates innate colonic function: Barrier integrity and inflammation susceptibility

  • Simon P. Hogan, PhD

      Affiliations

    • From the Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
    • These authors contributed equally to this work.
    • ,
  • Luqman Seidu, MD

      Affiliations

    • From the Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
    • These authors contributed equally to this work.
    • ,
  • Carine Blanchard, PhD

      Affiliations

    • From the Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
    • ,
  • Katherine Groschwitz, BS

      Affiliations

    • Department of Immunobiology, University of Cincinnati College of Medicine
    • ,
  • Anil Mishra, PhD

      Affiliations

    • From the Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
    • ,
  • Margaret L. Karow, PhD

      Affiliations

    • Regeneron Pharmaceuticals, Inc, Tarrytown, NY
    • ,
  • Richard Ahrens, BS

      Affiliations

    • From the Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
    • ,
  • David Artis, PhD

      Affiliations

    • Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia
    • ,
  • Andrew J. Murphy, PhD

      Affiliations

    • Regeneron Pharmaceuticals, Inc, Tarrytown, NY
    • ,
  • David M. Valenzuela, PhD

      Affiliations

    • Regeneron Pharmaceuticals, Inc, Tarrytown, NY
    • ,
  • George D. Yancopoulos, MD, PhD

      Affiliations

    • Regeneron Pharmaceuticals, Inc, Tarrytown, NY
    • ,
  • Marc E. Rothenberg, MD, PhD

      Affiliations

    • From the Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
    • Corresponding Author InformationReprint requests: Marc E. Rothenberg, MD, PhD, Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, ML7028, Cincinnati OH 45229.

Received 16 March 2006 ,Revised 7 April 2006 ,Accepted 10 April 2006.

References 

  1. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925
  2. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma: an epidemic of dysregulated immunity. Nat Immunol. 2002;3:715–720
  3. Abelson P, Kennedy D. The obesity epidemic. Science. 2004;304:1413
  4. Weiss ST, Shore S. Obesity and asthma: directions for research. Am J Respir Crit Care Med. 2004;169:963–968
  5. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312
  6. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A. 2001;98:502–506
  7. Flier JS. The missing link with obesity?. Nature. 2001;409:292–293
  8. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 2000;19:4046–4055
  9. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science. 2004;304:1154–1158
  10. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, et al. Regulation of fasted blood glucose by resistin. Science. 2004;303:1195–1198
  11. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest. 2003;111:225–230
  12. Schinke T, Haberland M, Jamshidi A, Nollau P, Rueger JM, Amling M. Cloning and functional characterization of resistin-like molecule gamma. Biochem Biophys Res Commun. 2004;314:356–362
  13. Artis D, Wang ML, Keilbaugh SA, He W, Brenes M, Swain GP, et al. RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc Natl Acad Sci U S A. 2004;101:13596–13600
  14. Marcus RC, Matthews GA, Gale NW, Yancopoulos GD, Mason CA. Axon guidance in the mouse optic chiasm: retinal neurite inhibition by ephrin “A”-expressing hypothalamic cells in vitro. Dev Biol. 2000;221:132–147
  15. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–264
  16. Stevceva L, Pavli P, Husband A, Matthaei KI, Young IG, Doe WF. Eosinophilia is attentuated in experimental colitis induced in IL-5 deficient mice. Genes Immun. 2000;1:213–218
  17. Ten Hove T, Drillenburg P, Wijnholds J, te Velde AA, van Deventer SJ. Differential susceptibility of multidrug resistance protein-1 deficient mice to DSS and TNBS-induced colitis. Dig Dis Sci. 2002;47:2056–2063
  18. Camoglio L, te Velde AA, de Boer A, ten Kate FJ, Kopf M, van Deventer SJ. Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur J Immunol. 2000;30:1486–1495
  19. Rothenberg ME, Luster AD, Lilly CM, Drazen JM, Leder P. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J Exp Med. 1995;181:1211–1216
  20. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098–1106
  21. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110:993–1002
  22. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733–5744
  23. Mashimo H, Wu DC, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 1996;274:262–265
  24. Forbes E, Murase T, Yang M, Matthaei KI, Lee JJ, Lee NA, et al. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol. 2004;172:5664–5675
  25. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94
  26. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev. 2003;3:521–533
  27. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549
  28. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterol. 1994;107:1643–1652
  29. Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest. 2003;111:291–297
  30. Okamoto H. The REG gene family and REG proteins: with special attention to the regeneration of pancreatic B-cells. J Hepatobiliary Pancreat Surg. 1999;6:254–262
  31. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999;11:648–656
  32. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?. Gut. 2006;55:342–347
  33. Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterol. 1997;113:802–807
  34. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet. 1993;341:1437–1439
  35. Gironella M, Iovanna JL, Sans M, Gil F, Penalva M, Closa D, et al. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut. 2005;54:1244–1253
  36. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest. 2005;115:3057–3071
  37. Wang ML, Shin ME, Knight PA, Artis D, Silberg DG, Suh E, et al. Regulation of RELM/FIZZ isoform expression by Cdx2 in response to innate and adaptive immune stimulation in the intestine. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1074–G1083
  38. Brasch-Andersen C, Haagerup A, Borglum AD, Vestbo J, Kruse TA. Highly significant linkage to chromosome 3q13.31 for rhinitis and related allergic diseases. J Med Gen. 2006;43:10–17
  39. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest. 2003;111:1863–1874
  40. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol. 2003;111:227–242

 Supported in part by the DDRDC Pilot and Feasibility Grant (NIH R24 DK64403; S.P.H.), R01 AI42242 (M.E.R.), AI45898 (M.E.R.), AI53479 (M.E.R.), and the Burroughs Wellcome Fund (M.E.R.) RO1 AI61570 (D.A.) and the Crohn's and Colitis Foundation of America's William and Shelby Modell Family Foundation Research Award (D.A.), and T32 AI060515 (L.S.).Disclosure of potential conflict of interest: A. Mishra has received grant support from the National Institutes of Health. A. J. Murphy owns stock in and is employed by Regeneron Pharmaceuticals, Inc. M. E. Rothenberg owns stock in Ception Therapeutics, is the inventor of a patent application filed by CCHMC concerning RELM-β, has received grant support from Cambridge Antibody Technology, and is on the speakers' bureau for Merck. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(06)00932-8

doi: 10.1016/j.jaci.2006.04.039

The Journal of Allergy and Clinical Immunology
Volume 118, Issue 1 , Pages 257-268 , July 2006

Article Tools

* Image Usage & Resolution